The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | A real-world analysis of the outcomes of patients with PNH treated with iptacopan
Iptacopan was the first oral complement inhibitor approved by the US Food and Drug Administration (FDA) for the management of patients with paroxysmal nocturnal hemoglobinuria (PNH). Carmelo Gurnari, MD, Cleveland Clinic, Cleveland, OH, outlines the findings of a real-world analysis of data from patients treated with this agent, either as first-line treatment or after prior intravenous therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
